Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
National Institute on Drug Abuse (NIDA)
With
New York MDRU
The objective of this study is to determine the safety and efficacy of a buprenorphine/naloxone combination tablet for opiate dependence treatment.
Age
18–59
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
DSM-IV diagnosis of current opiate dependence males and non-pregnant, non-nursing female 18-59 yrs of age
You may not be if
Any significant medical condition AST or ALT levels greater than 3x's the upper limit of normal level Current Axis I diagnosis other than opiate, caffeine or nicotine dependence
